DK1411124T3 - Humant cancerantigen fra tyrosinase-beslægtet protein 1 og gener, der koder dette - Google Patents

Humant cancerantigen fra tyrosinase-beslægtet protein 1 og gener, der koder dette

Info

Publication number
DK1411124T3
DK1411124T3 DK03022671T DK03022671T DK1411124T3 DK 1411124 T3 DK1411124 T3 DK 1411124T3 DK 03022671 T DK03022671 T DK 03022671T DK 03022671 T DK03022671 T DK 03022671T DK 1411124 T3 DK1411124 T3 DK 1411124T3
Authority
DK
Denmark
Prior art keywords
recognized
antigen
cancer
peptide
derived
Prior art date
Application number
DK03022671T
Other languages
Danish (da)
English (en)
Inventor
Rong-Fu Wang
Steven A Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1411124T3 publication Critical patent/DK1411124T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03022671T 1996-02-09 1997-02-06 Humant cancerantigen fra tyrosinase-beslægtet protein 1 og gener, der koder dette DK1411124T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/599,602 US5840839A (en) 1996-02-09 1996-02-09 Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US08/725,736 US5831016A (en) 1996-02-09 1996-10-04 Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

Publications (1)

Publication Number Publication Date
DK1411124T3 true DK1411124T3 (da) 2008-08-04

Family

ID=24400301

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03022671T DK1411124T3 (da) 1996-02-09 1997-02-06 Humant cancerantigen fra tyrosinase-beslægtet protein 1 og gener, der koder dette
DK97907609T DK0882130T5 (da) 1996-02-09 1997-02-06 Humant cancerantigen i tyrosinase-beslægtet protein 1 og gen, der koder dette

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97907609T DK0882130T5 (da) 1996-02-09 1997-02-06 Humant cancerantigen i tyrosinase-beslægtet protein 1 og gen, der koder dette

Country Status (12)

Country Link
US (4) US5840839A (xx)
EP (3) EP1092770A3 (xx)
JP (1) JP3998713B2 (xx)
AT (2) ATE251670T1 (xx)
AU (1) AU729497B2 (xx)
CA (2) CA2245702C (xx)
CY (1) CY2422B1 (xx)
DE (2) DE69725428T2 (xx)
DK (2) DK1411124T3 (xx)
ES (2) ES2206685T3 (xx)
PT (2) PT882130E (xx)
WO (1) WO1997029195A2 (xx)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
US6083703A (en) * 1996-02-09 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US6297253B1 (en) * 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US7335351B2 (en) * 1997-03-19 2008-02-26 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US6294344B1 (en) * 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP2085090A3 (en) * 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
US6043084A (en) * 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
EP1806403A3 (en) * 1997-10-08 2008-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
US7084239B1 (en) * 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
EP1021535B1 (en) * 1997-10-08 2007-03-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human cancer antigen ny eso-1/cag-3 and gene encoding same
JP2001522603A (ja) * 1997-11-06 2001-11-20 ロシュ ダイアグノスティックス ゲーエムベーハー 腫瘍特異的抗原、その製造方法、ならびに免疫および診断のためのその使用
JP3559894B2 (ja) 1998-04-01 2004-09-02 日産自動車株式会社 樹脂製ウィンドウ及びその製法
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7052830B1 (en) 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
DE69940774D1 (de) * 1998-06-17 2009-06-04 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
CN1318447C (zh) * 1998-06-25 2007-05-30 伊东恭悟 得自亲环蛋白b的肿瘤抗原肽
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US7030212B1 (en) * 1998-07-31 2006-04-18 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
AU6027399A (en) * 1998-09-04 2000-03-27 Ludwig Institute For Cancer Research An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor
WO2000024778A1 (en) * 1998-10-26 2000-05-04 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
US7148324B1 (en) * 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
EP1165778B1 (en) * 1999-03-11 2006-10-18 GlaxoSmithKline Biologicals S.A. Uses of casb618 polynucleotides and polypeptides
US6389376B1 (en) * 1999-07-26 2002-05-14 Sun Microsystems, Inc. Method and apparatus for generating n-segment steiner trees
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
JP4540033B2 (ja) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および／または増強する方法
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
US7354992B2 (en) * 1999-11-30 2008-04-08 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7795379B2 (en) * 1999-11-30 2010-09-14 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US6774226B1 (en) * 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
JP4776852B2 (ja) 2000-01-28 2011-09-21 アメリカ合衆国 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ
ATE513913T1 (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
EP1355926A2 (en) * 2000-05-31 2003-10-29 Genzyme Corporation Therapeutic compounds for ovarian cancer
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002010369A1 (fr) * 2000-07-31 2002-02-07 Kyogo Itoh Antigene associe aux tumeurs
EP1309373A2 (en) * 2000-08-11 2003-05-14 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
JP4503801B2 (ja) * 2000-09-08 2010-07-14 独立行政法人科学技術振興機構 新規ヒト癌・精巣抗原及びその遺伝子
WO2002042325A2 (en) * 2000-10-31 2002-05-30 Zycos Inc. Cyp1b1 nucleic acids and methods of use
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
DE10061299A1 (de) * 2000-12-08 2002-06-27 Siemens Ag Vorrichtung zur Feststellung und/oder Weiterleitung zumindest eines Umwelteinflusses, Herstellungsverfahren und Verwendung dazu
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
WO2002068653A2 (en) * 2001-02-26 2002-09-06 Imclone Systems Incorporated Tri-hybrid melanoma antigen
EP2295074A1 (en) * 2001-03-07 2011-03-16 Mannkind Corporation Anti-neovasculature preparations for treating cancer
US8198400B2 (en) 2001-03-27 2012-06-12 Oncothyreon, Inc. Vaccine for modulating between T1 and T2 immune responses
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
WO2002086071A2 (en) * 2001-04-20 2002-10-31 Ludwig Institute For Cancer Research Cancer-testis antigens
WO2002097044A2 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
ES2330202T5 (es) * 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
US7202045B2 (en) * 2001-09-19 2007-04-10 Regents Of The University Of Michigan Detection and treatment of cancers of the lung
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
US20030119079A1 (en) * 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US7449548B2 (en) * 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
US20030148285A1 (en) * 2001-12-20 2003-08-07 Claude Perreault Mammalian SIMP protein, gene sequence and uses thereof in cancer therapy
DE60326931D1 (de) * 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
DE10221411B4 (de) * 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
AU2003297039B2 (en) 2002-12-13 2009-03-05 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
EP2933334B1 (en) 2003-02-18 2019-09-18 Baylor College of Medicine Induced activation in dendritic cells
ES2527946T3 (es) * 2003-03-05 2015-02-02 Dendreon Corporation Composiciones y métodos que emplean polipéptidos de marco de lectura alternativa para el tratamiento de cáncer y enfermedades infecciosas
DK1608762T3 (da) * 2003-03-20 2014-04-07 Alphavax Inc Forbedrede alphavirusreplikoner og hjælperkonstrukter
EP1651666B1 (en) * 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
WO2005010035A2 (en) * 2003-07-22 2005-02-03 Branch Andrea D Alternate reading frame polypeptides derived from hepatitis c and methods of their use
DE602004031116D1 (de) * 2003-07-22 2011-03-03 Ludwig Inst For Cancer Res New York Von hla-klasse-ii-molekülen präsentierte ssx-2-peptide
CA2542327C (en) * 2003-10-14 2014-08-12 Biomira, Inc. Combination therapy for cancer
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
EP2186896B1 (en) * 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US8084592B2 (en) * 2005-06-17 2011-12-27 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
EP2385060A3 (en) * 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2007015171A2 (en) * 2005-06-28 2007-02-08 Biomira, Inc. Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
HUE027330T2 (en) * 2005-07-27 2016-09-28 Oncotherapy Science Inc The TOM34 gene for colon cancer
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CA2630023A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
DE602006015508D1 (de) * 2005-11-16 2010-08-26 Pantarhei Bioscience Bv Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) * 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
EP2465510B1 (en) 2006-10-19 2018-11-28 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
US7850977B2 (en) 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies
WO2009149094A2 (en) * 2008-06-02 2009-12-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
BRPI0913612B8 (pt) 2008-06-05 2021-05-25 Immunovaccine Technologies Inc composição injetável de vacina, método para obter a composição e uso da composição
WO2010028066A2 (en) 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Cd133 epitopes
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
US8465756B2 (en) * 2009-08-12 2013-06-18 National Health Research Institutes Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN103339253B (zh) 2010-12-02 2015-09-09 肿瘤疗法科学股份有限公司 Tomm34肽及包含它们的疫苗
AU2012222188A1 (en) 2011-02-24 2013-08-15 Oncothyreon Inc. MUC1 based glycolipopeptide vaccine with adjuvant
EP2763698B1 (en) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
US10988516B2 (en) * 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9653272B2 (en) 2012-06-26 2017-05-16 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
PT2932264T (pt) * 2012-12-14 2019-05-21 Biontech Rna Pharmaceuticals Gmbh Novos antigénios independentes de mhc associados a tumor
EP2956544B1 (en) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Cancer vaccines and vaccination methods
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
AU2014228405B2 (en) * 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
AU2014242916B2 (en) 2013-03-28 2018-08-02 Invectys A cancer vaccine for dogs
EP2978445B1 (en) 2013-03-28 2018-07-04 Invectys A cancer vaccine for cats
AU2014274916B2 (en) 2013-06-05 2019-10-31 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
DK3063280T3 (da) 2013-10-28 2019-11-11 Invectys Genelektrooverførsel ind i hudceller
JP6545162B2 (ja) 2013-10-28 2019-07-17 アンヴェクティＩｎｖｅｃｔｙｓ テロメラーゼをコードするｄｎａワクチン
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
EP3189148A4 (en) 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
PT3193917T (pt) * 2014-09-17 2021-10-20 Io Biotech Aps Composições de vacina compreendendo triptofano-2,3-dioxigenase ou fragmentos desta
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
CN107531755B (zh) * 2015-01-16 2022-02-25 美侬米克国际有限公司 磷脂酰肌醇蛋白聚糖表位及其用途
JP6028253B2 (ja) * 2015-01-28 2016-11-16 学校法人北里研究所 癌細胞の検出方法及び癌細胞検出キット
JP2018510627A (ja) 2015-03-10 2018-04-19 レイデン ユニバーシティ メディカル センター メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
US20170119820A1 (en) 2015-07-31 2017-05-04 Regents Of The University Of Minnesota Modified cells and methods of therapy
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
WO2018208849A1 (en) 2017-05-09 2018-11-15 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
US11351246B2 (en) 2017-05-09 2022-06-07 Invectys SAS Recombinant measles vaccine expressing hTERT
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2019113509A2 (en) 2017-12-08 2019-06-13 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
CN109293739B (zh) * 2018-01-24 2021-03-30 中国疾病预防控制中心病毒病预防控制所 一种a3超家族通用肿瘤抗原多肽及其应用
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
WO2019222073A1 (en) 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
WO2020061203A1 (en) 2018-09-21 2020-03-26 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
CA2139517A1 (en) * 1992-07-20 1994-02-03 Paul M. Keller Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation

Also Published As

Publication number Publication date
EP0882130B1 (en) 2003-10-08
ATE391780T1 (de) 2008-04-15
CA2245702C (en) 2011-10-04
PT882130E (pt) 2004-02-27
US6087110A (en) 2000-07-11
AU729497B2 (en) 2001-02-01
CA2733866C (en) 2015-01-27
EP1092770A2 (en) 2001-04-18
EP1092770A3 (en) 2003-06-04
DE69725428T2 (de) 2004-07-29
CA2245702A1 (en) 1997-08-14
WO1997029195A3 (en) 1997-11-13
ES2206685T3 (es) 2004-05-16
PT1411124E (pt) 2008-07-04
ATE251670T1 (de) 2003-10-15
CY2422B1 (en) 2004-11-12
JP3998713B2 (ja) 2007-10-31
US5831016A (en) 1998-11-03
DE69738630T2 (de) 2009-05-07
US6132980A (en) 2000-10-17
JP2000506380A (ja) 2000-05-30
ES2305379T3 (es) 2008-11-01
EP1411124A2 (en) 2004-04-21
US5840839A (en) 1998-11-24
AU1957297A (en) 1997-08-28
CA2733866A1 (en) 1997-08-14
EP1411124B1 (en) 2008-04-09
EP0882130A2 (en) 1998-12-09
WO1997029195A2 (en) 1997-08-14
DK0882130T5 (da) 2004-05-17
DK0882130T3 (da) 2004-03-08
EP1411124A3 (en) 2004-09-29
DE69725428D1 (de) 2003-11-13
DE69738630D1 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
DK1411124T3 (da) Humant cancerantigen fra tyrosinase-beslægtet protein 1 og gener, der koder dette
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
NZ511454A (en) Immunotherapeutic methods using epitopes of WT-1 and GATA-1 for the treatment of cancers including leukaemia
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DK0932678T3 (da) En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåde til anvendelse deraf
ES8708015A1 (es) Un procedimiento para preparar relaxina -h2 humana o uno de sus analogos
ATE356206T1 (de) Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
ES8802160A1 (es) Un procedimiento para aislar un gen de relaxina cromosomica de un ser humano o de otro primate o una especie afin
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2000020447A3 (en) Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
CA2432971A1 (en) Polypeptides
WO2001008635A3 (en) Calcium channel transport polynucleotides, polypeptides, and antibodies
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
WO2002044202A3 (fr) Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques
EP1233024A3 (en) 25466, a human transporter family member and uses therefor
MY127669A (en) Polypeptide hormone phosphatonin
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2002088378A3 (en) 66784, a novel human potassium channel and uses therefor
Niewold et al. Equine light-chain-associated amyloidosis
Fillat et al. OVEREXPRESSION OF FROM FERREDOXIN-NADP+ REDUCTASE Anabaena sp. PCC 7119 IN E. coli.
WO2001042286A3 (en) Human leucine rich repeat-containing polypeptide and uses therefor
EP1679372A4 (en) NEW PLEXIN POLYPEPTIDE, THIS CODING DNA AND USE THEREOF
EP1264843A3 (en) 38554, 57301 and 58324, Human organic ion transporters and uses therefor
WO2001090327A3 (en) 21910, a membrane-associated guanylate kinase and uses thereof